Expanding the inhibitor space of the WWP1 and WWP2 HECT E3 ligases

Ashley P. Dudey, Jake M. Rigby, Gregory R. Hughes, G. Richard Stephenson, Thomas E. Storr, Andrew Chantry, Andrew M. Hemmings

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)
4 Downloads (Pure)

Abstract

The HECT E3 ubiquitin ligases 1 (WWP1) and 2 (WWP2) are responsible for the ubiquitin-mediated degradation of key tumour suppressor proteins and are dysregulated in various cancers and diseases. Here we expand their limited inhibitor space by identification of NSC-217913 displaying a WWP1 IC50 of 158.3 µM (95% CI = 128.7, 195.1 µM). A structure-activity relationship by synthesis approach aided by molecular docking led to compound 11 which displayed increased potency with an IC50 of 32.7 µM (95% CI = 24.6, 44.3 µM) for WWP1 and 269.2 µM (95% CI = 209.4, 347.9 µM) for WWP2. Molecular docking yielded active site-bound poses suggesting that the heterocyclic imidazo[4,5-b]pyrazine scaffold undertakes a π-stacking interaction with the phenolic group of tyrosine, and the ethyl ester enables strong ion-dipole interactions. Given the therapeutic potential of WWP1 and WWP2, we propose that compound 11 may provide a basis for future lead compound development.
Original languageEnglish
Article number2394895
JournalJournal of Enzyme Inhibition and Medicinal Chemistry
Volume39
Issue number1
Early online date2 Sept 2024
DOIs
Publication statusPublished - 3 Sept 2024

Keywords

  • ubiquitin ligase inhibitors
  • drug discovery
  • SAR
  • WWP1
  • WWP2

Cite this